Skip to main content Back to Top


Fluorescein Sodium Injection

Reason for the Shortage

    • Akorn ceased operations in February 2023.
    • Alcon has Fluorescite 10% injection available.
    • Nexus launched fluorescein 10% injection in late-October 2023. The company plans to launch the 25% fluorescein 2 mL vials in March 2024.
    • Long Grove Pharmaceuticals acquired AK-Fluor from Akorn. Before Long Grove acquired the drug Akorn ceased manufacturing. Long Grove is coordinating with FDA to distribute the inventory Akorn had made prior to their closure. More information can be found at:

Available Products

    • AK-Fluor laryngeal solution for injection, Long Grove Pharmaceuticals, 25%, 2 mL vial, 12 count, NDC 17478-0250-20
    • AK-Fluor solution for injection, Long Grove Pharmaceuticals, 10%, 5 mL vial, 12 count, NDC 17478-0253-10
    • Fluorescite solution for injection, Alcon Labs, 10%, 5 mL vial, 12 count, NDC 00065-0092-65
    • Fluorescein sodium solution for injection, Nexus Pharmaceuticals, 10%, 5 mL vial, 12 count, NDC 14789-0122-05

Estimated Resupply Dates

    • All marketed presentations are available.

Alternative Agents & Management

    • Indigotindisulfonate sodium (Bludigo) is labeled for use as a visualization aid in cytoscopic assessment of the integrity of the ureters in adults following urological and gynecological open, robotic, or endoscopic surgical procedures.


    1. Lexi-Drugs Online. Hudson, OH: Lexi-Comp, Inc.; 2023. Accessed June 19, 2023.


Updated December 14, 2023 by Leslie Jensen, PharmD, Drug Information Specialist. Created March 17, 2023 by Leslie Jensen, PharmD, Drug Information Specialist. © 2023, Drug Information Service, University of Utah, Salt Lake City, UT.


Drug Shortage Bulletins are copyrighted by the Drug Information Service of the University of Utah and provided by ASHP as its exclusive authorized distributor. ASHP and the University of Utah make no representations or warranties, express or implied, including, but not limited to, any implied warranty of merchantability and/or fitness for a particular purpose, with respect to such information, and specifically disclaim all such warranties. Users of this information are advised that decisions regarding the use of drugs and drug therapies are complex medical decisions and that in using this information, each user must exercise his or her own independent professional judgment. Neither ASHP nor the University of Utah assumes any liability for persons administering or receiving drugs or other medical care in reliance upon this information, or otherwise in connection with this Bulletin. Neither ASHP nor the University of Utah endorses or recommends the use of any particular drug. Any application of this information for any purpose shall be limited to personal, non-commercial use.

« Back to Drug Shortage Product Bulletins

ahfs logo

Subscribe to AHFS Clinical Drug Information to get direct access to integrated drug shortages content, plus comprehensive and actionable drug information.